NCT01609023View on ClinicalTrials.gov

A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia

CompletedOBSERVATIONAL
Enrollment

67

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Lymphocytic Leukemia, Chronic
Interventions
DRUG

Rituximab

Rituximab will be administered in combination with chemotherapy according to SPC and routine clinical practice.

Trial Locations (9)

18547

Metropolitan Hospital; Hematology Dept, Athens

26335

General Hospital of Patras Agios Andreas; Hematology Department, Pátrai

41110

University Hospital of Larissa; Hematology Dept., Larissa

68100

University General Hospital of Alexandroupolis; Haemotology, Alexandroupoli

106 76

General Hospital of Athens Evangelismos; Hematology, Athens

115 27

Laiko General Hospital of Athens; A Propedeutical Clinic of Internal Medicine, Athens

711 10

Periph. University General Hospital of Heraklion; Hematology, Heraklion

265 00

University Hospital Of Patras; Dept. Of Internal Medicine-Hematology Division, Pátrai

570 10

Georgios Papanikolaou Hospital; Hematology Department, Thessaloniki

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01609023 - A Study of Rituximab (MabThera) in Combination With Chemotherapy in Participants With CD20-Positive B-Cell Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter